 | • レポートコード：MRC2-11QY01525 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、150ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はIBS-C薬のグローバル市場について調査・分析したレポートです。種類別（リナクロチド、ルビプロストン、浸透圧性下剤、覚醒剤下剤、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別IBS-C薬の競争状況、市場シェア ・世界のIBS-C薬市場：種類別市場規模 2015年-2020年（リナクロチド、ルビプロストン、浸透圧性下剤、覚醒剤下剤、その他） ・世界のIBS-C薬市場：種類別市場規模予測 2021年-2026年（リナクロチド、ルビプロストン、浸透圧性下剤、覚醒剤下剤、その他） ・世界のIBS-C薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界のIBS-C薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米のIBS-C薬市場分析：米国、カナダ ・ヨーロッパのIBS-C薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのIBS-C薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のIBS-C薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのIBS-C薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Catalent Pharmaceuticals Solutions、Nestle、Abbott Laboratories、Synergy Pharmaceuticals、Sucampo Pharmaceuticals、Novartis Pharma、Astellas Pharmaceuticals、Ardelyx、Synthetic Biologics、Teva Pharmaceutical Industries、Bama-Geve、Ferring BV、Ironwood Pharmaceuticals、Salix Pharmaceuticals、Norgine、Prometheus Laboratories、Actavis Nordic、Albireo Pharma、Yuhan Corp、Astrazeneca、The Menarini Group、Ono Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
IBS‑C is defined as belly pain (abdominal pain) associated with constipation. The symptoms of IBS‑C are defined as long-lasting and keep coming back. Those suffering from IBS‑C also have hard or lumpy stools at least 25% of the time, and loose or watery stools less than 25% of the time.
The important driver increasing growth in the Global Irritable Bowel Syndrome with Constipation drugs Market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation include high intake of foods like insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and this loss of water through urination can also lead to IBS.
Market Analysis and Insights: Global IBS-C Drug Market
The global IBS-C Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global IBS-C Drug Scope and Market Size
IBS-C Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the IBS-C Drug market is segmented into
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Segment by Application, the IBS-C Drug market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional and Country-level Analysis
The IBS-C Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the IBS-C Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and IBS-C Drug Market Share Analysis
IBS-C Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in IBS-C Drug business, the date to enter into the IBS-C Drug market, IBS-C Drug product introduction, recent developments, etc.
The major vendors covered:
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma
Astellas Pharmaceuticals
Ardelyx
Synthetic Biologics
Teva Pharmaceutical Industries
Bama-Geve
Ferring BV
Ironwood Pharmaceuticals
Salix Pharmaceuticals
Norgine
Prometheus Laboratories
Actavis Nordic
Albireo Pharma
Yuhan Corp
Astrazeneca
The Menarini Group
Ono Pharmaceutical
1 Study Coverage
1.1 IBS-C Drug Product Introduction
1.2 Market Segments
1.3 Key IBS-C Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global IBS-C Drug Market Size Growth Rate by Type
1.4.2 Linaclotide
1.4.3 Lubiprostone
1.4.4 Osmotic Laxatives
1.4.5 Stimulant Laxatives
1.4.6 Other
1.5 Market by Application
1.5.1 Global IBS-C Drug Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global IBS-C Drug Market Size, Estimates and Forecasts
2.1.1 Global IBS-C Drug Revenue 2015-2026
2.1.2 Global IBS-C Drug Sales 2015-2026
2.2 Global IBS-C Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global IBS-C Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global IBS-C Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global IBS-C Drug Competitor Landscape by Players
3.1 IBS-C Drug Sales by Manufacturers
3.1.1 IBS-C Drug Sales by Manufacturers (2015-2020)
3.1.2 IBS-C Drug Sales Market Share by Manufacturers (2015-2020)
3.2 IBS-C Drug Revenue by Manufacturers
3.2.1 IBS-C Drug Revenue by Manufacturers (2015-2020)
3.2.2 IBS-C Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global IBS-C Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by IBS-C Drug Revenue in 2019
3.2.5 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 IBS-C Drug Price by Manufacturers
3.4 IBS-C Drug Manufacturing Base Distribution, Product Types
3.4.1 IBS-C Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers IBS-C Drug Product Type
3.4.3 Date of International Manufacturers Enter into IBS-C Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global IBS-C Drug Market Size by Type (2015-2020)
4.1.1 Global IBS-C Drug Sales by Type (2015-2020)
4.1.2 Global IBS-C Drug Revenue by Type (2015-2020)
4.1.3 IBS-C Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global IBS-C Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global IBS-C Drug Sales Forecast by Type (2021-2026)
4.2.2 Global IBS-C Drug Revenue Forecast by Type (2021-2026)
4.2.3 IBS-C Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global IBS-C Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global IBS-C Drug Market Size by Application (2015-2020)
5.1.1 Global IBS-C Drug Sales by Application (2015-2020)
5.1.2 Global IBS-C Drug Revenue by Application (2015-2020)
5.1.3 IBS-C Drug Price by Application (2015-2020)
5.2 IBS-C Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global IBS-C Drug Sales Forecast by Application (2021-2026)
5.2.2 Global IBS-C Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global IBS-C Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America IBS-C Drug by Country
6.1.1 North America IBS-C Drug Sales by Country
6.1.2 North America IBS-C Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America IBS-C Drug Market Facts & Figures by Type
6.3 North America IBS-C Drug Market Facts & Figures by Application
7 Europe
7.1 Europe IBS-C Drug by Country
7.1.1 Europe IBS-C Drug Sales by Country
7.1.2 Europe IBS-C Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe IBS-C Drug Market Facts & Figures by Type
7.3 Europe IBS-C Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific IBS-C Drug by Region
8.1.1 Asia Pacific IBS-C Drug Sales by Region
8.1.2 Asia Pacific IBS-C Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific IBS-C Drug Market Facts & Figures by Type
8.3 Asia Pacific IBS-C Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America IBS-C Drug by Country
9.1.1 Latin America IBS-C Drug Sales by Country
9.1.2 Latin America IBS-C Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America IBS-C Drug Market Facts & Figures by Type
9.3 Central & South America IBS-C Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa IBS-C Drug by Country
10.1.1 Middle East and Africa IBS-C Drug Sales by Country
10.1.2 Middle East and Africa IBS-C Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa IBS-C Drug Market Facts & Figures by Type
10.3 Middle East and Africa IBS-C Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Catalent Pharmaceuticals Solutions
11.1.1 Catalent Pharmaceuticals Solutions Corporation Information
11.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
11.1.3 Catalent Pharmaceuticals Solutions Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
11.1.5 Catalent Pharmaceuticals Solutions Related Developments
11.2 Nestle
11.2.1 Nestle Corporation Information
11.2.2 Nestle Description and Business Overview
11.2.3 Nestle Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Nestle IBS-C Drug Products Offered
11.2.5 Nestle Related Developments
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Corporation Information
11.3.2 Abbott Laboratories Description and Business Overview
11.3.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Abbott Laboratories IBS-C Drug Products Offered
11.3.5 Abbott Laboratories Related Developments
11.4 Synergy Pharmaceuticals
11.4.1 Synergy Pharmaceuticals Corporation Information
11.4.2 Synergy Pharmaceuticals Description and Business Overview
11.4.3 Synergy Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Synergy Pharmaceuticals IBS-C Drug Products Offered
11.4.5 Synergy Pharmaceuticals Related Developments
11.5 Sucampo Pharmaceuticals
11.5.1 Sucampo Pharmaceuticals Corporation Information
11.5.2 Sucampo Pharmaceuticals Description and Business Overview
11.5.3 Sucampo Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Sucampo Pharmaceuticals IBS-C Drug Products Offered
11.5.5 Sucampo Pharmaceuticals Related Developments
11.6 Novartis Pharma
11.6.1 Novartis Pharma Corporation Information
11.6.2 Novartis Pharma Description and Business Overview
11.6.3 Novartis Pharma Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novartis Pharma IBS-C Drug Products Offered
11.6.5 Novartis Pharma Related Developments
11.7 Astellas Pharmaceuticals
11.7.1 Astellas Pharmaceuticals Corporation Information
11.7.2 Astellas Pharmaceuticals Description and Business Overview
11.7.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Astellas Pharmaceuticals IBS-C Drug Products Offered
11.7.5 Astellas Pharmaceuticals Related Developments
11.8 Ardelyx
11.8.1 Ardelyx Corporation Information
11.8.2 Ardelyx Description and Business Overview
11.8.3 Ardelyx Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Ardelyx IBS-C Drug Products Offered
11.8.5 Ardelyx Related Developments
11.9 Synthetic Biologics
11.9.1 Synthetic Biologics Corporation Information
11.9.2 Synthetic Biologics Description and Business Overview
11.9.3 Synthetic Biologics Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Synthetic Biologics IBS-C Drug Products Offered
11.9.5 Synthetic Biologics Related Developments
11.10 Teva Pharmaceutical Industries
11.10.1 Teva Pharmaceutical Industries Corporation Information
11.10.2 Teva Pharmaceutical Industries Description and Business Overview
11.10.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Teva Pharmaceutical Industries IBS-C Drug Products Offered
11.10.5 Teva Pharmaceutical Industries Related Developments
11.1 Catalent Pharmaceuticals Solutions
11.1.1 Catalent Pharmaceuticals Solutions Corporation Information
11.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
11.1.3 Catalent Pharmaceuticals Solutions Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
11.1.5 Catalent Pharmaceuticals Solutions Related Developments
11.12 Ferring BV
11.12.1 Ferring BV Corporation Information
11.12.2 Ferring BV Description and Business Overview
11.12.3 Ferring BV Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Ferring BV Products Offered
11.12.5 Ferring BV Related Developments
11.13 Ironwood Pharmaceuticals
11.13.1 Ironwood Pharmaceuticals Corporation Information
11.13.2 Ironwood Pharmaceuticals Description and Business Overview
11.13.3 Ironwood Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Ironwood Pharmaceuticals Products Offered
11.13.5 Ironwood Pharmaceuticals Related Developments
11.14 Salix Pharmaceuticals
11.14.1 Salix Pharmaceuticals Corporation Information
11.14.2 Salix Pharmaceuticals Description and Business Overview
11.14.3 Salix Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Salix Pharmaceuticals Products Offered
11.14.5 Salix Pharmaceuticals Related Developments
11.15 Norgine
11.15.1 Norgine Corporation Information
11.15.2 Norgine Description and Business Overview
11.15.3 Norgine Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Norgine Products Offered
11.15.5 Norgine Related Developments
11.16 Prometheus Laboratories
11.16.1 Prometheus Laboratories Corporation Information
11.16.2 Prometheus Laboratories Description and Business Overview
11.16.3 Prometheus Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Prometheus Laboratories Products Offered
11.16.5 Prometheus Laboratories Related Developments
11.17 Actavis Nordic
11.17.1 Actavis Nordic Corporation Information
11.17.2 Actavis Nordic Description and Business Overview
11.17.3 Actavis Nordic Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Actavis Nordic Products Offered
11.17.5 Actavis Nordic Related Developments
11.18 Albireo Pharma
11.18.1 Albireo Pharma Corporation Information
11.18.2 Albireo Pharma Description and Business Overview
11.18.3 Albireo Pharma Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Albireo Pharma Products Offered
11.18.5 Albireo Pharma Related Developments
11.19 Yuhan Corp
11.19.1 Yuhan Corp Corporation Information
11.19.2 Yuhan Corp Description and Business Overview
11.19.3 Yuhan Corp Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Yuhan Corp Products Offered
11.19.5 Yuhan Corp Related Developments
11.20 Astrazeneca
11.20.1 Astrazeneca Corporation Information
11.20.2 Astrazeneca Description and Business Overview
11.20.3 Astrazeneca Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Astrazeneca Products Offered
11.20.5 Astrazeneca Related Developments
11.21 The Menarini Group
11.21.1 The Menarini Group Corporation Information
11.21.2 The Menarini Group Description and Business Overview
11.21.3 The Menarini Group Sales, Revenue and Gross Margin (2015-2020)
11.21.4 The Menarini Group Products Offered
11.21.5 The Menarini Group Related Developments
11.22 Ono Pharmaceutical
11.22.1 Ono Pharmaceutical Corporation Information
11.22.2 Ono Pharmaceutical Description and Business Overview
11.22.3 Ono Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Ono Pharmaceutical Products Offered
11.22.5 Ono Pharmaceutical Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 IBS-C Drug Market Estimates and Projections by Region
12.1.1 Global IBS-C Drug Sales Forecast by Regions 2021-2026
12.1.2 Global IBS-C Drug Revenue Forecast by Regions 2021-2026
12.2 North America IBS-C Drug Market Size Forecast (2021-2026)
12.2.1 North America: IBS-C Drug Sales Forecast (2021-2026)
12.2.2 North America: IBS-C Drug Revenue Forecast (2021-2026)
12.2.3 North America: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.3 Europe IBS-C Drug Market Size Forecast (2021-2026)
12.3.1 Europe: IBS-C Drug Sales Forecast (2021-2026)
12.3.2 Europe: IBS-C Drug Revenue Forecast (2021-2026)
12.3.3 Europe: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific IBS-C Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: IBS-C Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: IBS-C Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: IBS-C Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America IBS-C Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: IBS-C Drug Sales Forecast (2021-2026)
12.5.2 Latin America: IBS-C Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: IBS-C Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa IBS-C Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: IBS-C Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: IBS-C Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: IBS-C Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key IBS-C Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 IBS-C Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. IBS-C Drug Market Segments
Table 2. Ranking of Global Top IBS-C Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global IBS-C Drug Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Linaclotide
Table 5. Major Manufacturers of Lubiprostone
Table 6. Major Manufacturers of Osmotic Laxatives
Table 7. Major Manufacturers of Stimulant Laxatives
Table 8. Major Manufacturers of Other
Table 9. Global IBS-C Drug Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global IBS-C Drug Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global IBS-C Drug Sales by Regions 2015-2020 (K Units)
Table 12. Global IBS-C Drug Sales Market Share by Regions (2015-2020)
Table 13. Global IBS-C Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global IBS-C Drug Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global IBS-C Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global IBS-C Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global IBS-C Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS-C Drug as of 2019)
Table 18. IBS-C Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. IBS-C Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers IBS-C Drug Price (2015-2020) (USD/Unit)
Table 21. IBS-C Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers IBS-C Drug Product Type
Table 23. Date of International Manufacturers Enter into IBS-C Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 26. Global IBS-C Drug Sales Share by Type (2015-2020)
Table 27. Global IBS-C Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global IBS-C Drug Revenue Share by Type (2015-2020)
Table 29. IBS-C Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 31. Global IBS-C Drug Sales Share by Application (2015-2020)
Table 32. North America IBS-C Drug Sales by Country (2015-2020) (K Units)
Table 33. North America IBS-C Drug Sales Market Share by Country (2015-2020)
Table 34. North America IBS-C Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America IBS-C Drug Revenue Market Share by Country (2015-2020)
Table 36. North America IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 37. North America IBS-C Drug Sales Market Share by Type (2015-2020)
Table 38. North America IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 39. North America IBS-C Drug Sales Market Share by Application (2015-2020)
Table 40. Europe IBS-C Drug Sales by Country (2015-2020) (K Units)
Table 41. Europe IBS-C Drug Sales Market Share by Country (2015-2020)
Table 42. Europe IBS-C Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe IBS-C Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 45. Europe IBS-C Drug Sales Market Share by Type (2015-2020)
Table 46. Europe IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 47. Europe IBS-C Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific IBS-C Drug Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific IBS-C Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific IBS-C Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific IBS-C Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific IBS-C Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific IBS-C Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America IBS-C Drug Sales by Country (2015-2020) (K Units)
Table 57. Latin America IBS-C Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa IBS-C Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America IBS-C Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 61. Latin America IBS-C Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 63. Latin America IBS-C Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa IBS-C Drug Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa IBS-C Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa IBS-C Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa IBS-C Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa IBS-C Drug Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa IBS-C Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa IBS-C Drug Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa IBS-C Drug Sales Market Share by Application (2015-2020)
Table 72. Catalent Pharmaceuticals Solutions Corporation Information
Table 73. Catalent Pharmaceuticals Solutions Description and Major Businesses
Table 74. Catalent Pharmaceuticals Solutions IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Catalent Pharmaceuticals Solutions Product
Table 76. Catalent Pharmaceuticals Solutions Recent Development
Table 77. Nestle Corporation Information
Table 78. Nestle Description and Major Businesses
Table 79. Nestle IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Nestle Product
Table 81. Nestle Recent Development
Table 82. Abbott Laboratories Corporation Information
Table 83. Abbott Laboratories Description and Major Businesses
Table 84. Abbott Laboratories IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Abbott Laboratories Product
Table 86. Abbott Laboratories Recent Development
Table 87. Synergy Pharmaceuticals Corporation Information
Table 88. Synergy Pharmaceuticals Description and Major Businesses
Table 89. Synergy Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Synergy Pharmaceuticals Product
Table 91. Synergy Pharmaceuticals Recent Development
Table 92. Sucampo Pharmaceuticals Corporation Information
Table 93. Sucampo Pharmaceuticals Description and Major Businesses
Table 94. Sucampo Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Sucampo Pharmaceuticals Product
Table 96. Sucampo Pharmaceuticals Recent Development
Table 97. Novartis Pharma Corporation Information
Table 98. Novartis Pharma Description and Major Businesses
Table 99. Novartis Pharma IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Novartis Pharma Product
Table 101. Novartis Pharma Recent Development
Table 102. Astellas Pharmaceuticals Corporation Information
Table 103. Astellas Pharmaceuticals Description and Major Businesses
Table 104. Astellas Pharmaceuticals IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Astellas Pharmaceuticals Product
Table 106. Astellas Pharmaceuticals Recent Development
Table 107. Ardelyx Corporation Information
Table 108. Ardelyx Description and Major Businesses
Table 109. Ardelyx IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Ardelyx Product
Table 111. Ardelyx Recent Development
Table 112. Synthetic Biologics Corporation Information
Table 113. Synthetic Biologics Description and Major Businesses
Table 114. Synthetic Biologics IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Synthetic Biologics Product
Table 116. Synthetic Biologics Recent Development
Table 117. Teva Pharmaceutical Industries Corporation Information
Table 118. Teva Pharmaceutical Industries Description and Major Businesses
Table 119. Teva Pharmaceutical Industries IBS-C Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Teva Pharmaceutical Industries Product
Table 121. Teva Pharmaceutical Industries Recent Development
Table 122. Bama-Geve Corporation Information
Table 123. Bama-Geve Description and Major Businesses
Table 124. Bama-Geve IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Bama-Geve Product
Table 126. Bama-Geve Recent Development
Table 127. Ferring BV Corporation Information
Table 128. Ferring BV Description and Major Businesses
Table 129. Ferring BV IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 130. Ferring BV Product
Table 131. Ferring BV Recent Development
Table 132. Ironwood Pharmaceuticals Corporation Information
Table 133. Ironwood Pharmaceuticals Description and Major Businesses
Table 134. Ironwood Pharmaceuticals IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 135. Ironwood Pharmaceuticals Product
Table 136. Ironwood Pharmaceuticals Recent Development
Table 137. Salix Pharmaceuticals Corporation Information
Table 138. Salix Pharmaceuticals Description and Major Businesses
Table 139. Salix Pharmaceuticals IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 140. Salix Pharmaceuticals Product
Table 141. Salix Pharmaceuticals Recent Development
Table 142. Norgine Corporation Information
Table 143. Norgine Description and Major Businesses
Table 144. Norgine IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 145. Norgine Product
Table 146. Norgine Recent Development
Table 147. Prometheus Laboratories Corporation Information
Table 148. Prometheus Laboratories Description and Major Businesses
Table 149. Prometheus Laboratories IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 150. Prometheus Laboratories Product
Table 151. Prometheus Laboratories Recent Development
Table 152. Actavis Nordic Corporation Information
Table 153. Actavis Nordic Description and Major Businesses
Table 154. Actavis Nordic IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 155. Actavis Nordic Product
Table 156. Actavis Nordic Recent Development
Table 157. Albireo Pharma Corporation Information
Table 158. Albireo Pharma Description and Major Businesses
Table 159. Albireo Pharma IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 160. Albireo Pharma Product
Table 161. Albireo Pharma Recent Development
Table 162. Yuhan Corp Corporation Information
Table 163. Yuhan Corp Description and Major Businesses
Table 164. Yuhan Corp IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 165. Yuhan Corp Product
Table 166. Yuhan Corp Recent Development
Table 167. Astrazeneca Corporation Information
Table 168. Astrazeneca Description and Major Businesses
Table 169. Astrazeneca IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 170. Astrazeneca Product
Table 171. Astrazeneca Recent Development
Table 172. The Menarini Group Corporation Information
Table 173. The Menarini Group Description and Major Businesses
Table 174. The Menarini Group IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 175. The Menarini Group Product
Table 176. The Menarini Group Recent Development
Table 177. Ono Pharmaceutical Corporation Information
Table 178. Ono Pharmaceutical Description and Major Businesses
Table 179. Ono Pharmaceutical IBS-C Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 180. Ono Pharmaceutical Product
Table 181. Ono Pharmaceutical Recent Development
Table 182. Global IBS-C Drug Sales Forecast by Regions (2021-2026) (K Units)
Table 183. Global IBS-C Drug Sales Market Share Forecast by Regions (2021-2026)
Table 184. Global IBS-C Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 185. Global IBS-C Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 186. North America: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)
Table 187. North America: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 188. Europe: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)
Table 189. Europe: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 190. Asia Pacific: IBS-C Drug Sales Forecast by Region (2021-2026) (K Units)
Table 191. Asia Pacific: IBS-C Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 192. Latin America: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)
Table 193. Latin America: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 194. Middle East and Africa: IBS-C Drug Sales Forecast by Country (2021-2026) (K Units)
Table 195. Middle East and Africa: IBS-C Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 196. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 197. Key Challenges
Table 198. Market Risks
Table 199. Main Points Interviewed from Key IBS-C Drug Players
Table 200. IBS-C Drug Customers List
Table 201. IBS-C Drug Distributors List
Table 202. Research Programs/Design for This Report
Table 203. Key Data Information from Secondary Sources
Table 204. Key Data Information from Primary Sources
List of Figures
Figure 1. IBS-C Drug Product Picture
Figure 2. Global IBS-C Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Linaclotide Product Picture
Figure 4. Lubiprostone Product Picture
Figure 5. Osmotic Laxatives Product Picture
Figure 6. Stimulant Laxatives Product Picture
Figure 7. Other Product Picture
Figure 8. Global IBS-C Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. IBS-C Drug Report Years Considered
Figure 13. Global IBS-C Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global IBS-C Drug Sales 2015-2026 (K Units)
Figure 15. Global IBS-C Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global IBS-C Drug Sales Market Share by Region (2015-2020)
Figure 17. Global IBS-C Drug Sales Market Share by Region in 2019
Figure 18. Global IBS-C Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global IBS-C Drug Revenue Market Share by Region in 2019
Figure 20. Global IBS-C Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by IBS-C Drug Revenue in 2019
Figure 22. IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global IBS-C Drug Sales Market Share by Type (2015-2020)
Figure 24. Global IBS-C Drug Sales Market Share by Type in 2019
Figure 25. Global IBS-C Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global IBS-C Drug Revenue Market Share by Type in 2019
Figure 27. Global IBS-C Drug Market Share by Price Range (2015-2020)
Figure 28. Global IBS-C Drug Sales Market Share by Application (2015-2020)
Figure 29. Global IBS-C Drug Sales Market Share by Application in 2019
Figure 30. Global IBS-C Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global IBS-C Drug Revenue Market Share by Application in 2019
Figure 32. North America IBS-C Drug Sales Growth Rate 2015-2020 (K Units)
Figure 33. North America IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America IBS-C Drug Sales Market Share by Country in 2019
Figure 35. North America IBS-C Drug Revenue Market Share by Country in 2019
Figure 36. U.S. IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 37. U.S. IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 39. Canada IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America IBS-C Drug Market Share by Type in 2019
Figure 41. North America IBS-C Drug Market Share by Application in 2019
Figure 42. Europe IBS-C Drug Sales Growth Rate 2015-2020 (K Units)
Figure 43. Europe IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe IBS-C Drug Sales Market Share by Country in 2019
Figure 45. Europe IBS-C Drug Revenue Market Share by Country in 2019
Figure 46. Germany IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 47. Germany IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 49. France IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 51. U.K. IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 53. Italy IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 55. Russia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe IBS-C Drug Market Share by Type in 2019
Figure 57. Europe IBS-C Drug Market Share by Application in 2019
Figure 58. Asia Pacific IBS-C Drug Sales Growth Rate 2015-2020 (K Units)
Figure 59. Asia Pacific IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific IBS-C Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific IBS-C Drug Revenue Market Share by Region in 2019
Figure 62. China IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 63. China IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 65. Japan IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 67. South Korea IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 69. India IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 71. Australia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 73. Taiwan IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 75. Indonesia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 77. Thailand IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 79. Malaysia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 81. Philippines IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 83. Vietnam IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific IBS-C Drug Market Share by Type in 2019
Figure 85. Asia Pacific IBS-C Drug Market Share by Application in 2019
Figure 86. Latin America IBS-C Drug Sales Growth Rate 2015-2020 (K Units)
Figure 87. Latin America IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America IBS-C Drug Sales Market Share by Country in 2019
Figure 89. Latin America IBS-C Drug Revenue Market Share by Country in 2019
Figure 90. Mexico IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 91. Mexico IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 93. Brazil IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 95. Argentina IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America IBS-C Drug Market Share by Type in 2019
Figure 97. Latin America IBS-C Drug Market Share by Application in 2019
Figure 98. Middle East and Africa IBS-C Drug Sales Growth Rate 2015-2020 (K Units)
Figure 99. Middle East and Africa IBS-C Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa IBS-C Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa IBS-C Drug Revenue Market Share by Country in 2019
Figure 102. Turkey IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 103. Turkey IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 105. Saudi Arabia IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E IBS-C Drug Sales Growth Rate (2015-2020) (K Units)
Figure 107. U.A.E IBS-C Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa IBS-C Drug Market Share by Type in 2019
Figure 109. Middle East and Africa IBS-C Drug Market Share by Application in 2019
Figure 110. North America IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. North America IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Europe IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Asia Pacific IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Latin America IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa IBS-C Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Middle East and Africa IBS-C Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
副鼻腔治療薬の世界市場（～2026年） Market Analysis and Insights: Global Sinus Therapeutic Drug Market The global Sinus Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the repo…- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
- 遺伝性血管性浮腫薬の世界市場（～2026年） In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for tr…
- 成長ホルモン薬の世界市場（～2026年） Market Analysis and Insights: Global Growth Hormone Drug Market The global Growth Hormone Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Growth Hormone Drug Scope and Market Size Growth Hormone Drug market is seg…
- 過食症治療薬の世界市場（～2026年） Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusuall…